🇺🇸 FDA
Pipeline program

Hydrochloride anlotinib

CC-RT-ALTER-01

Unknown small_molecule active

Quick answer

Hydrochloride anlotinib for Uterine Cervical Neoplasms is a Unknown program (small_molecule) at Zhongnan Hospital with 1 ClinicalTrials.gov record(s).

Program details

Company
Zhongnan Hospital
Indication
Uterine Cervical Neoplasms
Phase
Unknown
Modality
small_molecule
Status
active

Clinical trials